Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Dirk M. Hermann, University of Duisburg-Essen, Germany

*CORRESPONDENCE Weilin Xu ⊠ 11618330@zju.edu.cn Anwen Shao ⊠ anwenshao@sina.com

RECEIVED 11 June 2023 ACCEPTED 20 June 2023 PUBLISHED 05 July 2023

CITATION

Xu W, Guo Z-N and Shao A (2023) Editorial: Ferroptosis in stroke, neurotrauma and neurodegeneration, volume II. *Front. Cell. Neurosci.* 17:1238425. doi: 10.3389/fncel.2023.1238425

COPYRIGHT

© 2023 Xu, Guo and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Ferroptosis in stroke, neurotrauma and neurodegeneration, volume II

Weilin Xu^{1,2*}, Zhen-Ni Guo³ and Anwen Shao^{1,2*}

¹Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, ²Key Laboratory of Precise Treatment and Clinical Translational Research of Neurological Diseases, Hangzhou, Zhejiang, China, ³Department of Neurology, The First Hospital of Jilin University, Changchun, China

KEYWORDS

ferroptosis, stroke, neurotrauma, neurodegeneration, cell death

Editorial on the Research Topic Ferroptosis in stroke, neurotrauma and neurodegeneration, volume II

Ferroptosis, a new form of cell death, is characterized by the accumulation of intracellular iron and lipid reactive oxygen species (ROS) (Deng et al., 2023). The primary morphologic manifestations of ferroptosis include cell volume shrinkage and increased mitochondrial membrane density. This process of ferroptosis differs from other apoptotic types of cell death such as necroptosis and pyroptosis (Costa et al., 2023). Growing evidence indicates that ferroptosis plays key roles in neurological diseases such as stroke, traumatic brain injury (TBI), and neurodegenerative diseases [Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), vascular dementia (VD), Huntington's disease (HD)] (Costa et al., 2023; Du et al., 2023). Ferroptosis inhibition has been shown to protect neurons and ameliorate cognitive impairment in various disease animal models (Li et al., 2022; Zhang et al., 2023). However, to date, the underlying mechanisms that how ferroptosis causes neurological injuries are still unclear. This Research Topic finally published nine studies, which extensively explored the relationships between ferroptosis and neurological diseases (stroke, TBI, and neurodegenerative diseases), including underlying mechanisms of ferroptosis, potential targeting, and the relationship between ferroptosis and other kinds of cell death (necroptosis and pyroptosis).

Ferroptosis and stroke

Zhu et al. adopted the method of bioinformatics analysis to explore the ferroptosisrelated ceRNA regulation network in intracranial aneurysm. They analyzed data from the Gene Expression Omnibus (GEO) datasets and tried to identify differentially expressed genes (DEGs), differentially expressed miRNAs (DEMs), and differentially expressed lncRNAs (DELs) in intracranial aneurysm. In all, 30 ferroptosis DEGs, five key DEMs, and 17 key DELs were screened and they found that CeRNA (PVT1-hsa-miR-4644-SLC39A14 and DUXAP8-hsa-miR-378e/378f-SLC2A3) overexpression networks were associated with ferroptosis in intracranial aneurysm. Pan et al. extensively elucidated the underlying mechanisms of ferroptosis in hemorrhagic stroke. They reported that ferroptosis plays important roles in the hemorrhagic stroke. The mechanisms include ion overloaded, lipid

peroxidation, and dysfunctional antioxidant system. Moreover, they also discussed the crosstalk between ferroptosis and other types of neuronal death or autophagy. Finally, they pointed out that ferroptosis marker detection, diversity of ferroptotic cell, and the uncertainty about the magnitude and duration of ferroptotic action are mainly the research dilemma and will be the research prospects of ferroptosis. The third study by Cao et al. also introduced the underlying mechanism and crosstalk of ferroptosis with other modes of neuronal death after intracerebral hemorrhage. Except for the overlaping content showed by Pan et al., Cao et al. discussed several therapeutic targets of inhibitors of ferroptosis in ICH, including selenium supplementation, iron chelators (DFX, VK-28, deferiprone), lipoxygenase inhibitors, and DMT1 inhibitor (Ebselen). The study by Chen et al. extensively introduced different patterns of neuronal death and their molecular mechanisms after subarachnoid hemorrhage (SAH), including necrosis, apoptosis, pyroptosis, autophagy, necroptosis, and ferroptosis. In ferroptosis, they emphatically introduced three primary anti-ferroptosis systems, GPX4-GSH-cysteine system, FSP1-CoQ10-NAD (P)H system and GCH1-BH4-DHFR system. These studies extensively demonstrated the underlying mechanisms of ferroptosis in stroke and its potential therapeutic targets, which provides key information for future study of ferroptosis in stroke.

Ferroptosis and neurodegenerative diseases

Among the rest, three studies emphasized the important roles of ferroptosis in neurodegenerative diseases. Wang et al. applied bioinformatic analysis to explore ferroptosis-related biomarkers for AD. They also analyzed the data from GEO datasets and performed enrichment analyses of protein-protein interaction (PPI), the Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Twenty-four ferroptosisrelated genes were identified as target genes. Finally, ASNS and SENS2 are screened as potential diagnostic biomarkers for AD and provide additional evidence regarding the essential role of ferroptosis in AD. In another study, Fu et al. focused on investigating the expression pattern of ferroptosis and iron metabolism-related genes (FIRGs) in amyotrophic lateral sclerosis (ALS). They performed a conjoint analysis of bulk-RNA sequence and single-nucleus RNA sequence data using the datasets from GEO. Fifteen FIRGs was identified as target genes. Final analysis of bulk single-nucleus RNA-seq data showed that CHMP5 was expressed significantly higher in ALS than pathologically normal (PN), specifically in excitatory neuron populations. The third study comprehensively reviewed the relationship of ferroptosis and neurodegenerative diseases. Firstly, they introduced the mechanisms of ferroptosis, including transport and storage of iron in the brain, the glutamate/cysteine antiporter in ferroptosis and lipid peroxidation in ferroptosis. In the second part, they reviewed the roles of ferroptosis in each neurodegenerative disease, such as AD, vascular dementia (VD), PD, HD, ALS, and TBI. These three studies interestingly showed the molecular patterns and underlying mechanisms of ferroptosis in neurodegenerative diseases.

Ferroptosis and other neurological diseases

The remaining two studies provided another view of neuronal death in neurological diseases. Li et al. used bioinformatic analysis to identify cuproptosis-related genes (CRGs) on disease progression and the immune microenvironment in acute spinal cord injury (ASCI) patients. Their results showed that dihydrolipoamide dehydrogenase (DLD) affects the ASCI immune microenvironment by promoting copper toxicity, leading to increased peripheral M2 macrophage polarization and systemic immunosuppression. In the second study, Shi et al. demonstrated the underlying mechanisms of deep brain stimulation (DBS) for treatment of refractory obsessive-compulsive disorder (OCD).

In conclusion, ferroptosis plays important roles in various neurological diseases and its pathological mechanism is complicated. Ferroptosis differs from other apoptotic types of cell death (necrosis, apoptosis, pyroptosis, autophagy, necroptosis, and ferroptosis), however, it also connects with many physiological processes (apoptosis, autophagy, oxidative stress, inflammation). This Research Topic comprehensively discussed the underlying mechanisms and potential targets of ferroptosis in each neurological disease, which provides key insights for further study of ferroptosis in the central nervous system.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Funding

This work was funded by National Natural Science Foundation of China (82001231), Zhejiang Provincial Natural Science Foundation of China (LQ21H090009), and Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China under Grant (LHDMZ22H300014).

Acknowledgments

We thank all authors for their contributions for this topic.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Costa, I., Barbosa, D. J., Benfeito, S., Silva, V., Chavarria, D., Borges, F., et al. (2023). Molecular mechanisms of ferroptosis and their involvement in brain diseases. *Pharmacol. Ther.* 244, 108373. doi: 10.1016/j.pharmthera.2023. 108373

Deng, X., Wu, Y., Hu, Z., Wang, S., Zhou, S., Zhou, C., et al. (2023). The mechanism of ferroptosis in early brain injury after subarachnoid hemorrhage. *Front. Immunol.* 14, 1191826. doi: 10.3389/fimmu.2023. 1191826

Du, L., Wu, Y., Fan, Z., Li, Y., Guo, X., Fang, Z., et al. (2023). The role of ferroptosis in nervous system disorders. J. Integr. Neurosci. 22, 19. doi: 10.31083/j.jin2201019

Li, Y., Xiao, D., and Wang, X. (2022). The emerging roles of ferroptosis in cells of the central nervous system. *Front Neurosci.* 16, 1032140. doi: 10.3389/fnins.2022.1032140

Zhang, R. F., Zeng, M., Lv, N., Wang, L. M., Yang, Q. Y., Gan, J. L., et al. (2023). Ferroptosis in neurodegenerative diseases: inhibitors as promising candidate mitigators. *Eur. Rev. Med Pharmacol. Sci.* 27, 46–65. doi:10.26355/eurrev_202301_30852